论文部分内容阅读
目的探讨细胞外基质金属蛋白酶诱导因子(EMMPRIN)在子痫前期及子痫患者胎盘组织中的表达及其与子痫前期及子痫发病的关系。方法采用免疫组化链霉菌抗生物素蛋白-过氧化酶连接法和RT-PCR技术检测不同孕周的44例子痫前期(重度)孕妇(子痫前期组)、38例子痫孕妇(子痫组)和49例正常孕妇(正常妊娠组)胎盘组织中EMMPRIN蛋白及mRNA的表达。结果(1)EMMPRIN蛋白阳性表达：子痫前期组EMMPRIN蛋白表达中度阳性率为18%(8/44),强阳性率为9%(4/44)；子痫组EMMPRIN蛋白中度阳性率为21%(8/38),强阳性率为13%(5/38),两组分别比较,差异均无统计学意义(P＞0．05)。正常妊娠组EMMPRIN蛋白表达中度阳性率为12%(6/49),强阳性率为82%(40/49),与子痫前期组及子痫组比较,差异均有统计学意义(P＜0．001)。(2) EMMPRIN mRNA表达：子痫前期组孕晚期(37～40周)EMMPRIN mRNA为0．342±0．002,子痫组为0．344±0．023,两组比较,差异均无统计学意义(P＞0．05)。正常妊娠组孕晚期(37～40周) EMMPRIN mRNA为0．872±0．094,分别与子痫前期组及子痫组比较,差异均有统计学意义(P＜0．001)。结论子痫前期及子痫患者胎盘组织中EMMPRIN表达水平下降是子痫前期及子痫发病的重要原因；EMMPRIN可作为子痫前期及子痫发病的一个预测指标。
Objective To investigate the expression of extracellular matrix metalloproteinase inducer (EMMPRIN) in placenta of preeclampsia and eclampsia and its relationship with preeclampsia and eclampsia. Methods 44 cases of preeclampsia (severe preeclampsia group) and 38 cases of pregnant women with preeclampsia (eclampsia group) were detected by immunohistochemical streptavidin-peroxidase-linked method and RT-PCR. ) And 49 cases of normal pregnancy (normal pregnancy group) placenta tissue EMMPRIN protein and mRNA expression. Results (1) The positive expression of EMMPRIN protein: The positive expression rate of EMMPRIN protein in preeclampsia group was 18% (8/44), and the strong positive rate was 9% (4/44). The positive rate of EMMPRIN protein in eclampsia group 21% (8/38), and strong positive rate was 13% (5/38). There was no significant difference between the two groups (P> 0.05). The positive rate of EMMPRIN protein expression in normal pregnancy group was 12% (6/49) and strong positive rate was 82% (40/49), respectively, which were significantly different from those in preeclampsia group and eclampsia group (P <0.001). (2) EMMPRIN mRNA expression: EMMPRIN mRNA was 0.342 ± 0.002 in the third trimester (37 ~ 40 weeks) of preeclampsia group and 0.344 ± 0.023 in the eclampsia group, there was no statistical difference between the two groups Significance (P> 0.05). Compared with preeclampsia group and eclampsia group, EMMPRIN mRNA in normal pregnancy group was 0.872 ± 0.094 in the third trimester of pregnancy (37 ~ 40 weeks), the differences were statistically significant (P <0.001). Conclusions The decreased expression of EMMPRIN in placenta of preeclampsia and eclampsia is an important cause of preeclampsia and eclampsia. EMMPRIN may be used as a predictor of preeclampsia and eclampsia.